Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on Sep 13, 2023 3:36pm
137 Views
Post# 35634531

RE:RE:Seeking Alpha

RE:RE:Seeking AlphaThe author's argument is that the samples are too small to draw conclusions about the efficacy of pela.

He only looks at sample size and neglects the notion that we have a series of studies (at least 2) in both mBC and panc that showed the same kinds of remarkable results. That is an important point. Also he is implying that they do not have statistically significant results. I cannot remember if that is true, but I do know we have wildly better results than SOC on panc and similar results to SOC on mBC.

He says the results may be noise. What he means is a statistical fluke, that would go away in larger samples. But doing the studies twice is far more convincing.

So his arguments are simply saying the results are not proven yet. That is what ph 3 studies are for.

He also neglects the safety profile and versatility of pela. 

Finally he neglects the Pan Can endorsement of pela for their onging panc p3.


<< Previous
Bullboard Posts
Next >>